Long-term results of operative treatment of 191 patients with ulcers of gastric localization were studied at terms from 1 year to 10 years. In 40 patients with malignant ulcers the recurrent cancer appeared within 5 years after resection of the stomach, during the first year--in 95%. In a group of 19 patients with malignant ulcers not diagnosed before operation recurrent cancer has also appeared in half of the patients, but during the first year in 1/3 only. After resection of the stomach for benign ulcers (122 patients) cancer was revealed in 5 (3.7%) patients within 3 years. As the preoperative investigation fails to reliably exclude the appearance of early cancer in the gastric ulcer margin the authors speak in favor of wider indications for resection of the stomach and for performing the operations with the observation of all oncological requirements.
Download full-text PDF |
Source |
---|
Sci Rep
January 2025
Department of Hematology-Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA.
No consensus exists on the optimal therapy for resectable gastric cancer (GC) and gastroesophageal junction (GEJ) tumors, including the effectiveness of chemoradiotherapy versus perioperative chemotherapy (PC). Our study aimed to compare overall survival (OS) outcomes associated with the recommended treatment modalities for GC and GEJ tumors and evaluate treatment trends from 2010 to 2020. A national registry cohort identified patients with ≥ cT2 nonmetastatic GC and GEJ cancer.
View Article and Find Full Text PDFTransl Lung Cancer Res
December 2024
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Background: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), has been authorized for use in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to evaluate the effectiveness and safety of neoadjuvant osimertinib in individuals with resectable locally advanced NSCLC harboring EGFR mutation.
Methods: Ten centers located in mainland China took part in a single-arm, real-world, multicenter retrospective study (registration number: ChiCTR2100049954).
J Int Med Res
January 2025
The Department of Gastroenterology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
For gastric leiomyomas measuring ≥5 cm, endoscopic resection is necessary. The larger size of these tumors significantly impairs the resection field of view, increasing the risk of intraoperative bleeding and perforation and potentially leading to incomplete tumor removal. The combination of dental floss and tissue clip traction techniques is commonly used for resecting mucosal lesions but is rarely reported for submucosal tumors.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Gastroenterology, Pinderfields General Hospital, Wakefield, UK.
Giant colonic diverticulum is an uncommon presentation of colonic diverticular disease. It is characterised by the presence of a diverticulum exceeding 4 cm in size, with approximately 90% of the cases involving the sigmoid colon. Typically, diagnosis relies on CT of the abdomen and pelvis (CTAP).
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Department of Surgery, University of the Philippines, Philippine General Hospital, Manila, Philippines.
We present the case of a man in his 60s with hypertension, who had a 3-year history of an irreducible mass in the left inguinal area. The patient presented at the emergency room with left lower quadrant pain and scrotal pain. The clinical examination was not suggestive of an acute abdomen.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!